Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion type Assertion NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_head.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_provenance.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion evidence source_evidence_literature NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_provenance.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion SIO_000772 10805278 NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_provenance.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion wasDerivedFrom befree-2016 NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_provenance.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion wasGeneratedBy ECO_0000203 NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_provenance.